APPENDIX II Treatment According to DCLSG Protocol ALL-7
| Drug . | Dose . | Applied on Days* . |
|---|---|---|
| Protocol I | ||
| Prednisone (prephase orally) | 60 mg/m2 | −7-0 |
| Prednisone (orally) | 60 mg/m2 | 1-28 |
| Vincristine (IV) | 1.5 mg/m2 (max. 2 mg) | 8, 15, 22, 29 |
| Daunorubicin (IV) | 40 mg/m2 | 8, 15, 22, 29 |
| L-Asparaginase (IV) | 10,000 IU/m2 | 19, 22, 25, 28, 31, 34, 37, 40 |
| Cyclophosphamide (IV) | 1,000 mg/m2 | 43, 71 |
| Cytosine arabinoside | 75 mg/m2 | 45-48, 52-55, 59-62, 66-69 |
| 6-Mercaptopurine (orally) | 60 mg/m2 | 43-70 |
| Methotrexate (ith) | According to age* | −7, 1, 45, 59 |
| Protocol M | ||
| 6-Mercaptopurine (orally) | 25 mg/m2 | 1-56 |
| Methotrexate (24-h infusion)† | 5 g/m2 | 8, 22, 36, 50 |
| Methotrexate (ith) | According to age* | 8, 22, 36, 50 |
| Protocol E | ||
| Prednisone (orally) | 100 mg/m2 | 1-7, 15-21, 29-35, 43-49 |
| Cytosine arabinoside | 2,000 mg/m2 every 12 h | 1, 2, 29, 30 |
| Ifosfamide (1-h infusion) | 1,000 mg/m2 every 12 h | 15, 16, 43, 44 |
| Mitoxantrone (IV) | 10 mg/m2 | 1, 15, 29, 43 |
| Methotrexate (24-h infusion) | 5 g/m2 | 8, 22, 36, 50 |
| Methotrexate (ith) | According to age* | 8, 22, 36, 50 |
| Protocol II | ||
| Dexamethasone (orally) | 10 mg/m2 | 1-21 |
| Vincristine (IV) | 1.5 mg/m2 (max. 2 mg) | 8, 15, 22, 29 |
| Doxorubicin (IV) | 30 mg/m2 | 8, 15, 22, 29 |
| L-Asparaginase (IV) | 10,000 IU/m2 | 8, 11, 15, 18 |
| Cyclophosphamide (IV) | 1,000 mg/m2 | 36 |
| Cytosine arabinoside | 75 mg/m2 | 38-41, 45-48 |
| 6-Thioguanin (orally) | 60 mg/m2 | 36-49 |
| Methotrexate (ith) | According to age* | 38, 45 |
| Protocol S (late intensification) | ||
| Prednisone (orally) | 100 mg/m2 | 1-7, 15-21 |
| Vindesine (IV) | 3 mg/m2 (max. 5 mg) | 1, 8, 15, 22 |
| Teniposide (IV) | 150 mg/m2 | 1, 8, 15, 22 |
| Ifosfamide (IV) | 1,000 mg/m2 | 1, 2 |
| Cytosine arabinoside (3-h infusion) | 2,000 mg/m2 every 12 h | 15, 16 |
| Maintenance treatment up to 18 mo after diagnosis: | 6-Mercaptopurine 50 mg/m2 daily (orally) and methotrexate 20 mg/m2 weekly (orally) |
| Drug . | Dose . | Applied on Days* . |
|---|---|---|
| Protocol I | ||
| Prednisone (prephase orally) | 60 mg/m2 | −7-0 |
| Prednisone (orally) | 60 mg/m2 | 1-28 |
| Vincristine (IV) | 1.5 mg/m2 (max. 2 mg) | 8, 15, 22, 29 |
| Daunorubicin (IV) | 40 mg/m2 | 8, 15, 22, 29 |
| L-Asparaginase (IV) | 10,000 IU/m2 | 19, 22, 25, 28, 31, 34, 37, 40 |
| Cyclophosphamide (IV) | 1,000 mg/m2 | 43, 71 |
| Cytosine arabinoside | 75 mg/m2 | 45-48, 52-55, 59-62, 66-69 |
| 6-Mercaptopurine (orally) | 60 mg/m2 | 43-70 |
| Methotrexate (ith) | According to age* | −7, 1, 45, 59 |
| Protocol M | ||
| 6-Mercaptopurine (orally) | 25 mg/m2 | 1-56 |
| Methotrexate (24-h infusion)† | 5 g/m2 | 8, 22, 36, 50 |
| Methotrexate (ith) | According to age* | 8, 22, 36, 50 |
| Protocol E | ||
| Prednisone (orally) | 100 mg/m2 | 1-7, 15-21, 29-35, 43-49 |
| Cytosine arabinoside | 2,000 mg/m2 every 12 h | 1, 2, 29, 30 |
| Ifosfamide (1-h infusion) | 1,000 mg/m2 every 12 h | 15, 16, 43, 44 |
| Mitoxantrone (IV) | 10 mg/m2 | 1, 15, 29, 43 |
| Methotrexate (24-h infusion) | 5 g/m2 | 8, 22, 36, 50 |
| Methotrexate (ith) | According to age* | 8, 22, 36, 50 |
| Protocol II | ||
| Dexamethasone (orally) | 10 mg/m2 | 1-21 |
| Vincristine (IV) | 1.5 mg/m2 (max. 2 mg) | 8, 15, 22, 29 |
| Doxorubicin (IV) | 30 mg/m2 | 8, 15, 22, 29 |
| L-Asparaginase (IV) | 10,000 IU/m2 | 8, 11, 15, 18 |
| Cyclophosphamide (IV) | 1,000 mg/m2 | 36 |
| Cytosine arabinoside | 75 mg/m2 | 38-41, 45-48 |
| 6-Thioguanin (orally) | 60 mg/m2 | 36-49 |
| Methotrexate (ith) | According to age* | 38, 45 |
| Protocol S (late intensification) | ||
| Prednisone (orally) | 100 mg/m2 | 1-7, 15-21 |
| Vindesine (IV) | 3 mg/m2 (max. 5 mg) | 1, 8, 15, 22 |
| Teniposide (IV) | 150 mg/m2 | 1, 8, 15, 22 |
| Ifosfamide (IV) | 1,000 mg/m2 | 1, 2 |
| Cytosine arabinoside (3-h infusion) | 2,000 mg/m2 every 12 h | 15, 16 |
| Maintenance treatment up to 18 mo after diagnosis: | 6-Mercaptopurine 50 mg/m2 daily (orally) and methotrexate 20 mg/m2 weekly (orally) |